Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Last trade$2.40
Day change-$0.01 (-0.41%)
Day range$2.40 – $2.44
Volume97,507
Market cap$57M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$56.9M
Price / earnings
—
Price / book
0.92×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.39×
Profitability
Earnings per share
-$2.35
Return on assets
-87.27%
Return on equity
-89.91%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
33.97×
Quick ratio
33.97×
Cash ratio
18.65×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$57.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BOLD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.76M
$10.41M
$4.74M
$4.19M
$4.48M
$4.84M
$5.2M
$4.96M
Research and development
$1.44M
$13.97M
$9.73M
$9.82M
$10.67M
$12.22M
$12.14M
$13.31M
Total operating expenses
$6.2M
$24.38M
$14.48M
$14M
$15.15M
$17.06M
$17.34M
$18.28M
Operating income
-$6.2M
-$24.38M
-$14.48M
-$14M
-$15.15M
-$17.06M
-$17.34M
-$18.28M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$5.36M
-$23.69M
-$13.56M
-$12.89M
-$13.88M
-$15.68M
-$15.76M
-$16.45M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.36M
-$23.69M
-$13.56M
-$12.89M
-$13.88M
-$15.68M
-$15.76M
-$16.45M
Net income attributable to common shareholders
-$5.36M
-$23.69M
-$13.56M
-$12.89M
-$13.88M
-$15.68M
-$15.76M
-$16.45M
EBITDA
-$6.1M
-$23.13M
-$14.19M
-$13.7M
-$14.84M
-$16.74M
-$17.02M
-$17.98M
Basic earnings per share
-$0.23
-$1.06
-$0.60
-$0.58
-$0.62
-$0.70
-$0.71
-$0.73
Diluted earnings per share
-$0.23
-$1.06
-$0.60
-$0.58
-$0.62
-$0.70
-$0.71
-$0.73
Recent news
Company coverage with links to the original publishers.
Boundless Bio presented preclinical data supporting BBI-940, an oral kinesin degrader, as a potential first-in-class therapy for advanced or metastatic breast cancers. The compound targets a novel kinesin protein essential for extrachromosomal DNA (ecDNA) segregation in cancer cells but non-essential in healthy cells. Preclinical studies demonstrated tumor regressions in ecDNA-positive breast cancer models, with the Phase 1 KOMODO-1 clinical trial currently enrolling patients with ER+/HER2- and TNBC-LAR breast cancers.
Boundless Bio announced financial results for 2025 with $107.6 million in cash providing runway through mid-2028. The company's lead program BBI-940, a first-in-class oral Kinesin degrader, is actively enrolling patients in the KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR. The company reduced R&D expenses to $44.8 million for 2025 and narrowed net losses to $58.2 million. Boundless ceased enrollment in the POTENTIATE trial to prioritize BBI-940 development.
Boundless Bio announced that its novel Kinesin degrader BBI-940 received IND acceptance, with first-in-human clinical trials expected to begin in the first half of 2026. The company extended its operating runway through portfolio prioritization, including discontinuation of the POTENTIATE trial. CEO Zachary Hornby will participate in upcoming biotech industry conferences.
Boundless Bio, a clinical-stage oncology company, reported its Q1 2025 financial results and provided updates on its pipeline. The company has a cash position of $138.3 million, which is expected to fund operations into 2027. Boundless Bio is advancing its BBI-355 program, a CHK1 inhibitor, and its novel Kinesin program, with key milestones expected in 2025 and 2026.
Boundless Bio, a clinical-stage oncology company, announced that its President and CEO will participate in Needham's Virtual Healthcare Conference. The company is developing an oral inhibitor of checkpoint kinase 1 (CHK1) to target extrachromosomal DNA (ecDNA) in oncogene amplified cancers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.